Tumor Pathway Activations Inhibited by Dovitinib

Clinical trial pipeline · Data from ClinicalTrials.gov

See which Tumor Pathway Activations Inhibited by Dovitinib trials you may qualify for

Total trials

Actively recruiting

Phase 3 trials

Completed

Trial phase breakdown

Trial status

All recent trials (1 shown)

CompletedPhase 2

NCT01831726

Dovitinib for Patients With Tumor Pathway Activations Inhibited by Dovitinib

The purpose of this signal seeking study was to determine whether treatment with dovitinib (TKI258) demonstrated sufficient efficacy in select pathway-activated…

United States80 participantsStarted 2013-08

Treatment: Dovitinib (TKI258)